123 related articles for article (PubMed ID: 19954971)
1. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.
Harada K; Kubo H; Tomigahara Y; Nishioka K; Takahashi J; Momose M; Inoue S; Kojima A
Bioorg Med Chem Lett; 2010 Jan; 20(1):272-5. PubMed ID: 19954971
[TBL] [Abstract][Full Text] [Related]
2. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Day JM; Tutill HJ; Foster PA; Bailey HV; Heaton WB; Sharland CM; Vicker N; Potter BV; Purohit A; Reed MJ
Mol Cell Endocrinol; 2009 Mar; 301(1-2):251-8. PubMed ID: 18786604
[TBL] [Abstract][Full Text] [Related]
3. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Lawrence HR; Vicker N; Allan GM; Smith A; Mahon MF; Tutill HJ; Purohit A; Reed MJ; Potter BV
J Med Chem; 2005 Apr; 48(8):2759-62. PubMed ID: 15828812
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3).
Spires TE; Fink BE; Kick EK; You D; Rizzo CA; Takenaka I; Lawrence RM; Ruan Z; Salvati ME; Vite GD; Weinmann R; Attar RM; Gottardis MM; Lorenzi MV
Prostate; 2005 Oct; 65(2):159-70. PubMed ID: 15924334
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3).
Lota RK; Dhanani S; Owen CP; Ahmed S
Bioorg Med Chem Lett; 2006 Sep; 16(17):4519-22. PubMed ID: 16797984
[TBL] [Abstract][Full Text] [Related]
6. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Allan GM; Lawrence HR; Cornet J; Bubert C; Fischer DS; Vicker N; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2006 Feb; 49(4):1325-45. PubMed ID: 16480268
[TBL] [Abstract][Full Text] [Related]
7. Identification of oxazolidinediones and thiazolidinediones as potent 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
Harada K; Kubo H; Tanaka A; Nishioka K
Bioorg Med Chem Lett; 2012 Jan; 22(1):504-7. PubMed ID: 22137341
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors.
Harada K; Kubo H; Abe J; Haneta M; Conception A; Inoue S; Okada S; Nishioka K
Bioorg Med Chem; 2012 May; 20(10):3242-54. PubMed ID: 22512907
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
10. The design of novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors.
Vicker N; Sharland CM; Heaton WB; Gonzalez AM; Bailey HV; Smith A; Springall JS; Day JM; Tutill HJ; Reed MJ; Purohit A; Potter BV
Mol Cell Endocrinol; 2009 Mar; 301(1-2):259-65. PubMed ID: 18775469
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3.
Fink BE; Gavai AV; Tokarski JS; Goyal B; Misra R; Xiao HY; Kimball SD; Han WC; Norris D; Spires TE; You D; Gottardis MM; Lorenzi MV; Vite GD
Bioorg Med Chem Lett; 2006 Mar; 16(6):1532-6. PubMed ID: 16386902
[TBL] [Abstract][Full Text] [Related]
12. Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Djigoué GB; Kenmogne LC; Roy J; Maltais R; Poirier D
Bioorg Med Chem; 2015 Sep; 23(17):5433-51. PubMed ID: 26277760
[TBL] [Abstract][Full Text] [Related]
13. Development of 17β-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy.
Ning X; Yang Y; Deng H; Zhang Q; Huang Y; Su Z; Fu Y; Xiang Q; Zhang S
Steroids; 2017 May; 121():10-16. PubMed ID: 28267564
[TBL] [Abstract][Full Text] [Related]
14. Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.
Day JM; Tutill HJ; Purohit A; Reed MJ
Endocr Relat Cancer; 2008 Sep; 15(3):665-92. PubMed ID: 18541621
[TBL] [Abstract][Full Text] [Related]
15. Development of 3-substituted-androsterone derivatives as potent inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
Maltais R; Fournier MA; Poirier D
Bioorg Med Chem; 2011 Aug; 19(15):4652-68. PubMed ID: 21741247
[TBL] [Abstract][Full Text] [Related]
16. Novel estrone mimetics with high 17beta-HSD1 inhibitory activity.
Oster A; Klein T; Werth R; Kruchten P; Bey E; Negri M; Marchais-Oberwinkler S; Frotscher M; Hartmann RW
Bioorg Med Chem; 2010 May; 18(10):3494-505. PubMed ID: 20413314
[TBL] [Abstract][Full Text] [Related]
17. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics.
Marchais-Oberwinkler S; Kruchten P; Frotscher M; Ziegler E; Neugebauer A; Bhoga U; Bey E; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Aug; 51(15):4685-98. PubMed ID: 18630892
[TBL] [Abstract][Full Text] [Related]
18. 16-Picolyl-androsterone derivative exhibits potent 17β-HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies.
Cortés-Benítez F; Roy J; Perreault M; Maltais R; Poirier D
J Steroid Biochem Mol Biol; 2021 Jun; 210():105846. PubMed ID: 33609690
[TBL] [Abstract][Full Text] [Related]
19. E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Fischer DS; Allan GM; Bubert C; Vicker N; Smith A; Tutill HJ; Purohit A; Wood L; Packham G; Mahon MF; Reed MJ; Potter BV
J Med Chem; 2005 Sep; 48(18):5749-70. PubMed ID: 16134943
[TBL] [Abstract][Full Text] [Related]
20. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.
Ngatcha BT; Laplante Y; Labrie F; Luu-The V; Poirier D
Mol Cell Endocrinol; 2006 Mar; 248(1-2):225-32. PubMed ID: 16359782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
